Physician profile
Cesar Ramirez
$3,412.58
in general payments reported to CMS, 2019-2025
15 companies · $438 in 2025
The $438 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.97 · 2020: $22.28 · 2021: $65.73 · 2022: $855 · 2023: $684 · 2024: $1,309 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $933.81 | 2022-2025 | Lumigan |
| Alcon Vision LLC | $533.27 | 2020-2025 | Eysuvis, Clareon, Tryptyr |
| Novartis Pharmaceuticals Corporation | $312.90 | 2022-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $305.74 | 2023-2024 | Tecnis Simplicity, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $295.02 | 2021-2024 | Drizalma Sprinkle, Xelpros, Cequa |
| Harrow Eye, LLC | $267.71 | 2024 | Iheezo, Vevye |
| Bausch & Lomb Americas INC. | $181.24 | 2024 | Envista Mx60 Iol, Sofport Ao, Miebo |
| Oyster Point Pharma, INC. | $157.29 | 2022-2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $155.90 | 2024 | Xdemvy |
| Rayner Intraocular Lenses Limited | $78.80 | 2024 | Omidria, Rayone Emv, Rayone Aspheric |
| Kala Pharmaceuticals, INC. | $64.92 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $42.53 | 2023 | Flarex |
| Shire North American Group INC | $38.97 | 2019 | |
| Rxsight INC | $22.31 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Optos, INC. | $22.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.